CE Mark for ACURATE Prime Aortic Valve System, transcatheter aortic valve replacement (TAVR) technology
Boston Scientific Corporation announced it has obtained CE mark for the ACURATE Prime Aortic Valve System, the newest transcatheter aortic valve replacement (TAVR) technology in the company's structural heart portfolio
The ACURATE Prime valve system is designed with several features to build upon the clinical performance of the ACURATE neo2 platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.
The new ACURATE Prime valve system is indicated to restore function and normal blood flow through a narrowed aortic valve in low, intermediate and high-risk patients with severe aortic stenosis. With a self-expanding, supra-annular design, this device has an enhanced frame that equalizes force across the valve for a stable fit against the native, diseased valve. It also offers physicians a redesigned deployment mechanism for highly accurate valve positioning to help ensure positive patient outcomes.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.